BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27102929)

  • 41. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of chronic immune thrombocytopenic purpura with rituximab in children.
    Dogan M; Oner AF; Acikgoz M; Uner A
    Indian J Pediatr; 2009 Nov; 76(11):1141-4. PubMed ID: 20092026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reemergence of Splenectomy for ITP Second-line Treatment?
    Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P
    Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).
    Schwartz J; Leber MD; Gillis S; Giunta A; Eldor A; Bussel JB
    Am J Hematol; 2003 Feb; 72(2):94-8. PubMed ID: 12555211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia.
    Zoghlami-Rintelen C; Weltermann A; Bittermann C; Kyrle PA; Pabinger I; Lechner K; Wenzl E
    Ann Hematol; 2003 May; 82(5):290-4. PubMed ID: 12739064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
    Chemnitz JM; Uener J; Hallek M; Scheid C
    Ann Hematol; 2010 Oct; 89(10):1029-33. PubMed ID: 20422413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Rituximab and Dexamethasone Combined with Cyclophosphamide for Treatment of Relapsed and Refractory Immune Thrombocytopenia].
    Han XD; Zhou J; Yu FK; Fang BJ; Zhang YL; Wei XD; Song YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):162-6. PubMed ID: 26913414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura.
    Ellithy HN; Ahmed SH; Shahin GH; Matter MM; Talatt M
    Hematology; 2018 Apr; 23(3):169-174. PubMed ID: 28856973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The value of platelet count in predicting the efficacy of rituximab treatment in adult patients with chronic primary immune thrombocytopenia].
    Wang SX; Nie YB; Ju MK; Sun T; Li HY; Zhang DL; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):573-578. PubMed ID: 30122017
    [No Abstract]   [Full Text] [Related]  

  • 53. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
    Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
    Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.
    Reboursiere E; Fouques H; Maigne G; Johnson H; Chantepie S; Gac AC; Reman O; Macro M; Benabed K; Troussard X; Damaj G; Cheze S
    Int J Hematol; 2016 Jul; 104(1):85-91. PubMed ID: 27040278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
    Alasfoor K; Alrasheed M; Alsayegh F; Mousa SA
    Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical analysis of lower doses rituximab for children primary immune thrombocytopenia].
    Liu X; Huang Y; Chen Y; Liu W; Xue F; Zhang L; Yang R
    Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1079-82. PubMed ID: 25543701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.
    Marangon M; Vianelli N; Palandri F; Mazzucconi MG; Santoro C; Barcellini W; Fattizzo B; Volpetti S; Lucchini E; Polverelli N; Carpenedo M; Isola M; Fanin R; Zaja F
    Eur J Haematol; 2017 Apr; 98(4):371-377. PubMed ID: 27981682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.